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BACKGROUND The central nervous origins of functional para-
sympathetic innervation of cardiac ventricles remain controversial.
OBJECTIVE This study aimed to identify a population of vagal
preganglionic neurons that contribute to the control of ventricular
excitability. An animal model of synuclein pathology relevant to
Parkinson’s disease was used to determine whether age-related loss
of the activity of the identiﬁed group of neurons is associated with
changes in ventricular electrophysiology.
METHODS In vivo cardiac electrophysiology was performed in
anesthetized rats in conditions of selective inhibition of the dorsal
vagal motor nucleus (DVMN) neurons by pharmacogenetic approach
and in mice with global genetic deletion of all family members of
the synuclein protein.
RESULTS In rats anesthetized with urethane (in conditions of
systemic beta-adrenoceptor blockade), muscarinic and neuronal
nitric oxide synthase blockade conﬁrmed the existence of a tonic
parasympathetic control of cardiac excitability mediated by the
actions of acetylcholine and nitric oxide. Acute DVMN silencing led
to shortening of the ventricular effective refractory period (vERP), a
lowering of the threshold for triggered ventricular tachycardia, and
prolongation of the corrected QT (QTc) interval. Lower resting
activity of the DVMN neurons in aging synuclein-deﬁcient mice was
found to be associated with vERP shortening and QTc interval
prolongation.
CONCLUSION Activity of the DVMN vagal preganglionic neurons is
responsible for tonic parasympathetic control of ventricular excit-
ability, likely to be mediated by nitric oxide. These ﬁndings provide
the ﬁrst insight into the central nervous substrate that underlies
functional parasympathetic innervation of the ventricles and
highlight its vulnerability in neurodegenerative diseases.
KEYWORDS Arrhythmia; Atrioventricular; Brain; Cardiac
electrophysiology; Nitric oxide; parasympathetic; Parkinson’s
disease; Vagus nerve; Ventricle
ABBREVIATIONS 7-NI ¼ 7-Nitroindazole; AlstR ¼ allatostatin
receptor; AVNERP ¼ atrioventricular node effective recovery
period; DVMN ¼ dorsal vagal motor nucleus; eGFP ¼ enhanced
green ﬂuorescent protein; LVV ¼ lentiviral vector; NO ¼ nitric
oxide; nNOS ¼ neuronal nitric oxide synthase; QTc ¼ corrected QT
interval; SNRT ¼ sinus node recovery time; vERP ¼ ventricular
effective refractory period; VT¼ ventricular tachycardia;WT¼ wild
type
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Introduction
Sudden cardiac death is devastating for the family affected
and represents a signiﬁcant public health burden.1 Sudden
circulatory collapse is often attributable to malignant arrhy-
thmias, such as ventricular tachycardia (VT). Predictors of
sudden cardiac death include conventional coronary risk
factors and conditions such as congestive heart failure, as
well as markers of parasympathetic (vagal) dysfunction that
include reduced heart rate variability and reduced baroreﬂex
sensitivity.2,3 It is not surprising that vagus nerve stimulation
is being explored as a therapeutic option in heart failure, and
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one component of its potential beneﬁt may be an antiar-
rhythmic effect.4,5
Experimental studies in animal models have demon-
strated profound antiarrhythmic effects of vagus nerve
stimulation.6–8 It effectively reduces the restitution slope,
prevents alternans, and increases the ventricular effective
refractory period (vERP).6 Vagus nerve stimulation also
decreases the incidence of ventricular arrhythmia associated
with heightened sympathetic activity during myocardial
infarction.8 There is clinical evidence that vagal tone
suppresses an accelerated ventricular rhythm,9 and exper-
imental data show that the vagal inﬂuence on ventricular
refractoriness and arrhythmia threshold is tonic and could be
abolished by bilateral vagotomy or systemic muscarinic
receptor blockade.10 Studies from one of our laboratories
demonstrated that in mice, global genetic deletion of the
inhibitory G protein Gαi2 (which mediates muscarinic
inﬂuences on the heart) is associated with a reduced vERP,
a prolonged corrected QT interval (QTc), and a predisposi-
tion to VT.11 There is also evidence that the protective vagal
inﬂuence on cardiac electrical stability might be mediated by
nitric oxide (NO), produced by neuronal NO synthase
(nNOS).12,13
Despite this evidence, there has been no attempt to study
the central nervous mechanisms underlying parasympathetic
antiarrhythmic inﬂuences. In this study, we aimed to identify a
population of vagal preganglionic neurons that provide func-
tional parasympathetic innervation of the ventricles and
control ventricular excitability. Vagal preganglionic neurons
projecting to cardiac ganglia are located in the brainstem.
Neuronal tracing experiments in different species14,15 have
identiﬁed the dorsal vagal motor nucleus (DVMN) as one
such population of neurons with long-latency C-ﬁber axons
converging on cardiac plexuses.14 Because the activities of
DVMN neurons appear to protect ventricular cardiomyocytes
against acute ischemia/reperfusion injury,16 we hypothesized
that functional ventricular innervation is provided by DVMN
neuronal projections.
Autonomic dysfunction has emerging clinical impor-
tance contributing to the pathogenesis of Parkinson’s
disease.17,18 Parkinson’s disease is the second most com-
mon neurodegenerative disorder19 characterized by loss of
dopaminergic neurons, with consequent motor impairment
as well as DVMN dysfunction, which results in a host of
autonomic abnormalities.18,20 Aggregation of α-synuclein
is a major molecular event in the development of the disease
because of the toxicity of certain intermediate products of
this process. Age-dependent decline of substantia nigra pars
compacta synaptic function has been reported in α-synu-
clein–deﬁcient mice.21 These changes appeared to be even
more pronounced in triple-synuclein-null (αβγ/) mice
that have been generated to limit functional compensation
by other members of the synuclein family.22 In this study,
we used αβγ/ mice to determine whether synuclein
deﬁciency leads to a reduction in the activity of DVMN
neurons and has an impact on the electrophysiological
properties of the ventricle.
Methods
All experiments were performed in accordance with European
Commission Directive 2010/63/EU (European Convention for
the Protection of Vertebrate Animals Used for Experimental
and Other Scientiﬁc Purposes) and the UK Home Ofﬁce
(Scientiﬁc Procedures) Act (1986) with project approval from
the respective institutional animal care and use committee.
Cardiac electrophysiology
Cardiac pacing with extrastimulation was performed with a
Grass S88 stimulator (Grass Instruments/Natus Neurology,
Warwick, RI) as described in detail previously.11 Adult male
Sprague-Dawley rats (weight 380–450 g), wild-type (WT)
mice, and αβγ/ mice were anesthetized with urethane (1.3
g/kg IP), and an octapolar electrophysiology catheter (1.6F
for rats and 1.1F for mice) was positioned in the right atrium
and the right ventricle via the jugular vein or in the left
ventricle via the right common carotid artery. For assessment
of vERP, 10 paced beats (10 S1) were applied with a cycle
length of 85 ms in mice and 100 ms in rats, followed by a
gradually shortened extra single paced beat (S2) until failure
of ventricular capture. The maximum S1-S2 coupling
interval was measured as the vERP. VT threshold (in rats
only) was evaluated by application of 15 paced beats (15 
S1), with the cycle length shortened from 100 ms to 20 ms in
4ms increments (10–60 Hz burst pacing). One episode of VT
was deﬁned as at least 10 consecutive broad complex
systoles (all of which were noted to undergo self-cardiover-
sion). The deﬁnition of VT was similar to that in recent
publications.11
For assessment of the atrioventricular node effective
refractory period (AVNERP) in rats, 10 paced beats (10 
S1) with a cycle length of 141 ms were applied, followed by
a gradually shortened extra single paced beat (S2) until
failure of ventricular capture. The Wenckebach point was
determined by shortening the cycle length (from 150 ms)
until 2:1 block was observed. Sinus node recovery time
(SNRT) was measured as the period between the last paced
beat and the onset of the ﬁrst P wave after 30 seconds of atrial
pacing (cycle length 141 ms).
Pharmacological study
To determine the presence of a tonic parasympathetic
inﬂuence on cardiac electrical stability in the main exper-
imental model used in the present study (rat anesthetized
with urethane), systemic beta-adrenoceptor blockade was
applied (atenolol 2 mg  kg1  h1 IV), and the effects of
sequential systemic muscarinic (atropine methyl nitrate
2 mg1  kg1  h1 IV) and nNOS (7-nitroindazole [7-
NI]; 20 mg/kg IP) blockade on AVNERP, SNRP, Wenck-
ebach point, left and right vERP, and left and right VT were
determined.
Targeting vagal preganglionic neurons in the DVMN
Cholinergic vagal preganglionic neurons of the DVMN
characteristically express the transcriptional factor Phox2
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and can be targeted to express the gene of interest using viral
vectors with Phox2 activated promoter (PRSx8). DVMN
neurons were transduced with lentiviral vectors (LVVs) to
express either the Gi-protein–coupledDrosophila allatostatin
receptor (AlstR) or enhanced green ﬂuorescent protein
(eGFP; control). Application of a natural ligand of AlstR,
the insect peptide allatostatin, results in a highly selective,
rapid, and reversible silencing of the DVMN neurons
expressing AlstR.16
Male Sprague-Dawley rats (weight 50 g) were anesthetized
with ketamine (60 mg/kg IM) and medetomidine (250 μg/kg
IM). Adequate depth of surgical anesthesia was conﬁrmed by
the absence of a withdrawal response to a paw pinch. With the
head ﬁxed prone in the stereotaxic frame, the dorsal surface of
the brainstem was exposed. DVMN neurons were targeted
with 2 microinjections per side (0.25 μL; 0.05 μL/min) of a
solution containing viral particles of PRSx8-AlstR-eGFP-
LVV or PRSx8-eGFP-LVV. The injections were made at
0.5 mm rostral, 0.6 mm lateral, and 0.8 mm ventral and at 1.0
mm rostral, 0.8 mm lateral, and 0.6 mm ventral from the
calamus scriptorius. Anesthesia was reversed with atipame-
zole (1 mg/kg IM). For postoperative analgesia, rats were
administered buprenorphine (0.05 mg  kg1  d1 SC) for
3 days and carprofen (4 mg  kg1  d1 IP) for 5 days. One
rat injected with PRSx8-AlstR-eGFP-LVV developed middle
ear infection and was excluded from the study. Rats weighed
300 to 400 g at the time of the experiments.
Vagal preganglionic neurons transduced to express AlstR
along the left and right extent of the DVMNwere silenced by
allatostatin infusion into the cisterna magna (as described
previously16), and the effects of this treatment on vERP and
VT threshold were determined in conditions of intact
sympathetic tone.
In a separate experiment, conducted in conditions of
systemic beta-adrenoceptor (atenolol) and muscarinic (atro-
pine) blockade, atrial and ventricular pacing protocols were
applied before and after acute bilateral silencing of the
DVMN neurons by targeted microinjections of a potent
GABAA receptor agonist muscimol. Rats (n ¼ 8) were
anesthetized and instrumented for cardiac electrophysiology
as described above, and the heads were ﬁxed in the stereo-
taxic frame dorsal side up. An occipital craniotomy was
performed to expose dorsal brainstem. A multibarreled glass
micropipette (tip size 20–25 μm) was used for microinjec-
tions of a vehicle (saline) or muscimol (0.1 M; 40 nL; pH
7.4) into the left and right DVMN (coordinates: 0.3 mm
rostral, 0.7 mm lateral, and 0.8 mm ventral from the calamus
scriptorius). The injections were made using pressure over a
period of 5 to 10 seconds and were monitored by use of a
dissecting microscope with a calibrated micrometer disk.
Triple-synuclein–null (αβγ/) mice
Young (6 months old) and aging (12–18 months old) αβγ/
and age-matched WT mice were used to determine whether
synuclein deﬁciency is associated with a decline in DVMN
activity and consequential changes in ventricular excitability.
αβγ/ and WT mice were produced within the same
breeding program (on the C57Bl/6J genetic background) as
described previously.22 All 3 lines of single synuclein
knockout mice were backcrossed with C57Bl/6J (Charles
River, Wilmington, MA) for more than 8 generations before
intercrossing to obtain double-knockout and ﬁnally αβγ/
mice. WT littermates obtained from intercrosses were used
as controls.
Derivations of QT interval
Needle electrodes were used to acquire a lead II electro-
cardiogram (ECG). The ECG was acquired for 15 minutes
before programmed electrical stimulation and 15 minutes
after allatostatin applications in rats expressing AlstR or
eGFP in the DVMN, 15 minutes after saline or muscimol
microinjections into the DVMN, and in αβγ/ andWTmice
at baseline. In the pharmacological experiments, the ECG
was acquired for 15 minutes before and after administration
of each drug.
Three different approaches to deriving QTc were used
because of the established controversies concerning its
derivation in rodents.23,24 QTc was derived by (1) Bazett’s
formula: QTBC ¼ QTC√ RRCFð Þ (where RR is in milli-
seconds, and F = 100 ms for mice and 150 ms for rats)11,25;
(2) Fridericia cubic root formula: QTFC ¼ QT
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
RRCFð Þ3
p
(where F = 100 ms for mice and 150 ms for rats); and (3)
nomogram correction: QTNC ¼ QTþ0:384 150RRð Þ
for rats and QT þ 0.156  (100  RR) for mice.23,24 QTc
was analyzed with the Tukey-Kramer multiple comparison
test after 3-way analysis of variance to compare the effect of
constructs (rats) or genotype (mice), allatostatin/vehicle
(rats), age (mice), and QTc derivation formula. As a
surrogate measure of ventricular repolarization that avoided
rate dependency, raw QT measurements from vERP meas-
urements were also analyzed.
Humane endpoints
At the end of the experiments, the animals were euthanized
with an overdose of pentobarbital sodium (200 mg/kg IP).
Recording the activity of the DVMN neurons
Coronal brainstem slices (200 μm) were obtained from 12- to
18-month-old WT (n = 5) and αβγ/ (n = 4) mice
terminally anesthetized with halothane. Brains were dis-
sected in ice-cold low [Naþ] solution containing 200 mM
sucrose, 2.5 mMKCl, 28 mMNaHCO3, 1.25 mMNaH2PO4,
3 mM pyruvate, 7 mM MgCl2, 0.5 mM CaCl2, and 7 mM
glucose (pH 7.4). After recovery at 341C for 30 minutes in a
solution containing 118 mM NaCl, 3 mM KCl, 25 mM
NaHCO3, 1.2 mM NaH2PO4, 7 mM MgCl2, 0.5 mM CaCl2,
and 2.5 mM glucose (pH 7.4), slices were kept at 341C in
artiﬁcial cerebrospinal ﬂuid containing 118 mMNaCl, 3 mM
KCl, 25 mM NaHCO3, 1 mM MgCl2, 2 mM CaCl2, and 10
mM glucose saturated with 95% O2 and 5% CO2 (pH 7.4).
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Recording pipettes (3–6 MΩ) were pulled from thin-
walled borosilicate capillaries, and recordings were per-
formed in cell-attached mode with an EPC-9 ampliﬁer and
Pulse/Pulseﬁt software (Heka Elektronik, Lambrecht, Ger-
many). Electrodes were ﬁlled with 120 mM K-gluconate, 5
mM HEPES, 5 mM BAPTA, 1 mM NaCl, 1 mM MgCl2, 1
mM CaCl2, and 2 mM K2ATP (pH 7.2). Recordings were
performed in artiﬁcial cerebrospinal ﬂuid saturated with 95%
O2 and 5% CO2 at 281C to 321C. Currents were ﬁltered at 1
kHz and digitized at 3 kHz. Mean action potential frequency
was determined by taking the average frequency over a
period of 3 minutes. Recordings were analyzed with Strath-
clyde Electrophysiology Software (WinEDR/WinWCP;
University of Strathclyde, Glasgow, United Kingdom).
Data analysis
Data are expressed as mean  standard error. Interactions
between groups or treatments were analyzed with analysis of
variance with a Tukey-Kramer multiple comparison test,
nonparametric Mann-Whitney U test, or paired Student t test
as appropriate. DVMN neuronal recordings from each
animal were averaged and analyzed with a Wilcoxon rank
sum test for difference in medians.
Results
Parasympathetic inﬂuences on cardiac
electrophysiology mediated by acetylcholine
and nitric oxide are preserved under
urethane anesthesia
In conditions of beta-adrenoceptor blockade (atenolol),
atropine administration reduced AVNERP (62  6 vs 77
 3 ms at baseline; P = .003, Tukey-Kramer) (Figure 1A)
and SNRT (171  7 vs 219  5 ms at baseline; P ¼ .002,
Tukey-Kramer) (Figure 1B) and lowered the S1 coupling
interval required to achieve 2:1 heart block (64  1 vs 73 
2 ms at baseline; P¼ .0008, Tukey-Kramer) (Figure 1C). No
signiﬁcant changes were observed after subsequent systemic
nNOS blockade with 7-NI or during the course of the
experiment in the group of time/vehicle control animals
(Figure 1).
In the ventricular pacing paradigm (in conditions of
systemic beta-adrenoceptor blockade), atropine had no effect
on left or right vERP or VT (Figure 2). Addition of systemic
nNOS blockade was associated with a reduction of both left
(40 2 vs 49 2 ms at baseline; P ¼ .001, Tukey-Kramer)
(Figure 2A) and right (41 2 vs 49 2 ms at baseline; P ¼
.03, Tukey-Kramer) (Figure 2A) vERP. 7-NI administration
produced a modest QTc prolongation measured during vERP
assessment protocols in the left ventricle only (74  2 vs 67
 3 ms at baseline; P ¼ .02, Tukey-Kramer) (Figure 2B).
This was concordant with the surface ECG data pooled from
all atrial and ventricular pacing experiments, which revealed
a modest prolongation in 2 derivations of QTc (Online
Supplement Table 1). nNOS blockade also resulted in
lowering of the left (28  3 vs 54  3 ms at baseline;
P ¼ .0002, Tukey-Kramer) (Figure 2C) and right (45 6 vs
60 0 ms at baseline; P¼ .001, Tukey-Kramer) (Figure 2C)
VT thresholds.
Effect of DVMN silencing on cardiac
electrophysiology
Application of allatostatin in rats expressing AlstR in the
DVMN (Figure 3) resulted in vERP shortening (33 1 vs 42
 1 ms at baseline; P¼ .002, Tukey-Kramer) Figure 4A and
Figure 4B in the absence of heart rate changes (P ¼ .8)
(Online Supplemental Table 2). vERP reduction is known to
be proarrhythmic in situations of both reentry and triggered
activity. Analyses of averaged ECG waveforms revealed a
prolongation of QTc according to all 3 correction formulas
(P ¼ .028, Tukey-Kramer) (Online Supplemental Table 2)
(Figure 4C). Measurements obtained during the vERP
assessment protocol also revealed QT prolongation in
conditions of DVMN inhibition (60  4 vs 52  2 ms at
baseline; P¼ .04, Tukey-Kramer) (Figure 4D). VT threshold
(manifesting in this case as either monomorphic or poly-
morphic tachycardia) was lowered after DVMN inhibition
Figure 1 Tonic muscarinic inﬂuence on the electrical properties of nodal
tissue. Summary data obtained in rats anesthetized with urethane in
conditions of systemic beta-adrenoceptor blockade illustrating changes in
atrioventricular node effective refractory period (AVNERP; A), sinus node
recovery time (SNRT;B), and coupling interval required to achieve 2:1 heart
block (C) after sequential systemic administration of atropine methyl nitrate
(AMN) and neuronal nitric oxide synthase inhibitor 7-nitroindazole (7-NI)
or respective control vehicles (saline for AMN and peanut oil for 7-NI).
*Signiﬁcant difference compared with baseline values (P o .05).
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(22 4 vs 44 9 Hz at baseline; P ¼ .007, Tukey-Kramer)
Figure 4E and Figure 4F. Application of allatostatin in rats
expressing eGFP in the DVMN had no effect on vERP (42
4 vs 44 0.4 ms at baseline), VT threshold (51 6 vs 52
5 Hz at baseline), or QTc (Online Supplemental Table 2).
Four rats expressing eGFP remained negative for VT (up to
60 Hz) throughout the course of the experiment. Three
animals expressing AlstR in the DVMN that were negative
for VT before allatostatin administration displayed reduced
VT thresholds 30 minutes after application of the peptide.
In conditions of systemic beta-adrenoceptor and muscar-
inic blockade, inhibition of the DVMN neurons by bilateral
microinjections of muscimol reduced left vERP (45  22 vs
54  2 ms at baseline; P ¼ .02, Tukey-Kramer) and VT
threshold (51 4 vs 60 0 Hz at baseline; P ¼ .03, Tukey-
Kramer) (Figure 5). In these conditions (beta-adrenoceptor
and muscarinic blockade), DVMN inhibition resulted in a
small increase of SNRT (169 2 vs 162 2 ms at baseline;
P ¼ .02, Tukey-Kramer) and had no effect on AVNERP, the
coupling interval required to achieve 2:1 heart block, or QTc
(Figure 5).
Reduced activity of DVMN neurons in aging
αβγ/ mice is associated with changes
in ventricular excitability
Six-month-old αβγ/ mice and their WT counterparts
showed no signiﬁcant differences in cardiac electrophysiol-
ogy: both vERP (37 5 vs 37 3 ms) (Figure 6A) and ECG
features, including QTc, were similar. In contrast, 12- to 18-
month-old αβγ/mice displayed a shorter vERP (31 1 vs
43  3 ms in WT mice; P ¼ .002, Mann-Whitney U test)
(Figure 6B) and a prolonged QTc (P o .05) (Online
Supplemental Table 3) (Figure 6C). Electrophysiological
recordings taken from DVMN neurons in acute brainstem
slices showed a markedly reduced level of DVMN activity
(60%) in older αβγ/ mice (1.2 0.1 vs 2.3 0.2 Hz in
Figure 2 Tonic nitric oxide–mediated inﬂuence on the electrical properties of the
ventricles. Summary data obtained in rats anesthetizedwith urethane in conditions of
systemic beta-adrenoceptor blockade illustrating changes in left and right ventricular
effective refractory period (LvERP and RvERP; A), left ventricle (LV) and right
ventricle (RV) raw QT (QT500, measurements taken during vERP assessment
protocol; B), and left and right ventricular tachycardia (LVT and RVT) thresholds
after sequential systemic administration of atropine methyl nitrate (AMN) and 7-
nitroindazole (7-NI) or respective control vehicles (saline forAMNandpeanut oil for
7-NI; C). *Signiﬁcant difference compared with baseline values (Po .05).
Figure 3 Schematic showing location of the dorsal motor nucleus of the
vagus nerve (DVMN) in the rat brain. Bottom: Confocal image of coronal
section of the rat brainstem, targeted to express allatostatin receptor (AlstR)
in the DVMN. DVMN neurons are transduced to express AlstR-enhanced
green ﬂuorescent protein (eGFP). CC ¼ central canal.
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WT mice; P ¼ .04, Wilcoxon rank sum test) Figure 6D and
Figure 6E.
Discussion
The data obtained in the present study demonstrate that
reduced activity of DVMN vagal preganglionic neurons has
a signiﬁcant impact on cardiac electrical properties, with
changes consistent with the potential for ventricular arrhyth-
mogenesis. Acute and highly selective silencing of DVMN
neurons in a rat model was associated with vERP shortening
and reduced VT threshold. The absence of changes in R-R
and PR intervals, vERP shortening, and reduced VT
Figure 4 The effect of speciﬁc silencing of the dorsal vagal motor nucleus (DVMN) preganglionic neurons on ventricular excitability. A: Representative
in vivo cardiac electrophysiology data produced by programmed electrical stimulation (PES) showing an example of right ventricular effective refractory period
(RvERP) shortening in rats expressing the allatostatin receptor (AlstR) in DVMN after administration of allatostatin. B: Summary data illustrating RvERP
shortening after inhibition of DVMN neurons. C: Representative signal-averaged electrocardiogram recordings illustrating QT prolongation in rats expressing
AlstR in DVMN after administration of allatostatin.D: Summary data showing QT500 prolongation after inhibition of DVMN neurons.E: Representative in vivo
cardiac electrophysiology data produced by burst pacing in increasing frequencies showing an example of a lower ventricular tachycardia threshold in rats
expressing AlstR in DVMN after allatostatin application. F: Summary data illustrating decreased right ventricular tachycardia (RVT) threshold in rats after
DVMN silencing. eGFP ¼ rats expressing enhanced green ﬂuorescent protein in DVMN. *Signiﬁcant difference compared with baseline values (P o .05).
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Figure 5 Effect of bilateral inhibition of dorsal vagal motor nucleus (DVMN) neurons by targeted microinjections of muscimol on the electrical properties of the heart
in conditions of combined beta-adrenoceptor andmuscarinic blockade. Summary data illustrating atrioventricular node effective refractory period (AVNERP), sinus node
recovery time (SNRT), the coupling interval required to achieve 2:1 heart block, left ventricular effective refractory period (LvERP), left ventricular (LV) QT500, and LV
tachycardia (LVT) threshold values after bilateral saline and muscimol microinjections into DVMN. *Signiﬁcant difference compared with saline effect (Po .05).
Figure 6 Reduced activity of dorsal vagal motor nucleus (DVMN) neurons in aging triple-synuclein–null (αβγ/) mice is associated with changes in
ventricular excitability. A: At 6 months of age, there was no difference in right ventricular effective refractory period (RvERP) between wild-type (WT) and
αβγ/ mice. B: At 12 to 18 months, αβγ/ mice had a signiﬁcantly shorter RvERP than WT animals. C: Representative signal-averaged electrocardiography
recordings illustrating QT prolongation in αβγ/ mice. D: Representative recordings of electrical activity of DVMN neurons in WT and αβγ/ mice. E:
DVMN neurons of older αβγ/ mice have a signiﬁcantly reduced ﬁring frequency compared with age- and sex-matched WT counterparts. *Signiﬁcant
difference between WT and αβγ/ (P o .05).
2291Machhada et al Vagal Control of Ventricular Excitability
threshold with no associated reduction in AVNERP or SNRT
observed during DVMN silencing in conditions of beta-
adrenoceptor and muscarinic blockade would suggest pref-
erential innervation of the ventricles by DVMN neuronal
projections.
Tonic parasympathetic inﬂuence on cardiac electrical
stability is preserved in experimental animals kept under
urethane anesthesia. In conditions of beta-adrenoceptor
blockade, sequential systemic muscarinic and nNOS inhib-
ition conﬁrmed that vagal effects are mediated by the actions
of acetylcholine and NO. Systemic atropine administration
led to a reduction in AVNERP, SNRT, and coupling interval
required to achieve 2:1 heart block and had no effect on
vERP and VT. Systemic 7-NI treatment had no further effect
on AVNERP, SNRT, and coupling interval but led to a
signiﬁcant reduction in both left and right vERP and VT.
These data suggest that the vagal effects on cardiac electro-
physiology are mediated by a muscarinic mechanism at the
level of atria/nodal tissue and by NO at the level of the
ventricles. The latter conclusion is concordant with the recent
literature.12,13
This NO-mediated parasympathetic inﬂuence on the heart
appears to stem from the activity of the DVMN neurons.
Indeed, when DVMN was silenced in conditions of com-
bined muscarinic and beta-adrenoceptor blockade, only
reductions in vERP and VT (and not in AVNERP or SNRT)
were observed. We hypothesize that the cholinergic compo-
nent originates from the population of vagal preganglionic
neurons of the nucleus ambiguus, believed to provide the
most important source of phasic parasympathetic control of
the SA and AV nodes.26
Having previously demonstrated that synuclein deﬁ-
ciency results in age-dependent synaptic abnormalities,22
we used αβγ/ mice as a model of age-dependent auto-
nomic dysfunction relevant to Parkinson’s disease. In aging
αβγ/ mice, the reduced activity of DVMN neurons was
found to be associated with changes in ventricular excit-
ability similar to that observed in rats after acute DVMN
inhibition.
In both models (rats and mice), we also measured and
observed changes in the QTc interval. In general, we found a
prolongation associated with vagal withdrawal; however, the
magnitude of the recorded QTc changes varied depending on
the experimental protocol. There are a number of consid-
erations in interpreting these ﬁndings. The combination of
shortened vERP and prolonged QTc is paradoxical; how-
ever, we have observed this previously in mice with global
genetic deletion of Gαi2.11 We explained this by differences
in the rate dependence of changes in the dynamics of
repolarization. In addition, vERP and action potential
duration are not always strictly correlated.27 Finally, there
is some debate about the nature of the T wave in rodents and
how it relates to ventricular repolarization.28
There are some limitations to our study. The rodents do
not develop spontaneous arrhythmias, and we have not yet
developed techniques for chronic DVMN inhibition in
conscious rats that would allow longitudinal studies. Also,
rodents are not an ideal model for studying disorders of
cardiac repolarization, because the Kþ currents affected are
different in different species.29 Various murine models of
cardiac arrhythmia have been developed, such as those with
Naþ channel defects and autonomically driven arrhythmias
associated with engineered defects in Ca2þ handling.30
However, the basic organizational, developmental, and
signaling pathways between the brain and the heart are
broadly conserved across small and large mammals, which
gives the fundamental observations based on the reported
data a clear translational relevance.31
In summary, in this study, we used a rat model to
determine the effect of acute DVMN inhibition and a mouse
model to study the effect of age-dependent decline in DVMN
activity, relevant to the development of Parkinson’s disease.
Both models revealed that reduced activity of dorsal vagal
preganglionic neurons has a signiﬁcant impact on cardiac
electrical properties, with changes consistent with the devel-
opment of a ventricular proarrhythmic phenotype. The vagal
inﬂuence on ventricular excitability generated by the DVMN
is likely to be mediated by NO. These ﬁndings are the ﬁrst of
their kind to provide a fundamental insight into the central
nervous substrate that underlies functional parasympathetic
innervation of the ventricles and highlight its vulnerability in
neurodegenerative diseases.
Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at doi:10.1016/j.hrthm.2015.06.005.
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CLINICAL PERSPECTIVES
Synuclein-deﬁcient mice exhibit synaptic abnormalities with features similar to those observed in Parkinson’s disease and
so appear to be an appropriate model of age-related loss of DVMN activity. Indeed, in patients with Parkinson’s disease and
other neurodegenerative disorders, select neuronal populations such as the DVMN and substantia nigra pars compacta are
affected most signiﬁcantly. Loss of the DVMN activity would inevitably result in autonomic (parasympathetic) dysfunction
and, as our data suggest, would be sufﬁcient to have a signiﬁcant impact on ventricular excitability. Neurons with long
projecting axons with no myelination that require more energy for impulse propagation, like DVMN neurons, are the most
susceptible, especially in the sporadic variants of Parkinson’s disease. Results obtained in the present study provide an
insight into the central nervous substrate that underlies vagal control of cardiac ventricles and highlight its vulnerability in
neurodegenerative diseases.
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